Tidswell, Mark <br/><br/>
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.  [electronic resource] 

 -  Critical care medicine  Jan 2010 
 - 72-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1530-0293 
<br/><br/><label>Standard No.: </label>10.1097/CCM.0b013e3181b07b78  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>APACHE<br/>Adult<br/>Aged<br/>Bacterial Infections--diagnosis<br/>Cohort Studies<br/>Critical Care--methods<br/>Critical Illness--mortality<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Hospital Mortality--trends<br/>Humans<br/>Infusions, Intravenous<br/>Intensive Care Units<br/>Lipid A--administration & dosage<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Prospective Studies<br/>Risk Assessment<br/>Sepsis--diagnosis<br/>Survival Analysis<br/>Toll-Like Receptor 4--antagonists & inhibitors<br/>Treatment Outcome